Daniel M. Junius President and Chief Executive Officer

Daniel Junius joined ImmunoGen as Chief Financial Officer (CFO) and Senior Vice President, Finance in May 2005, was promoted to Executive Vice President, Finance and CFO in July 2006, to President and Chief Operating Officer in July 2008, and to President and Chief Executive Officer effective January 1, 2009.

Mr. Junius was Executive Vice President and CFO of New England Business Service, Inc. (NEBS) from 1998 until its acquisition by Deluxe Corporation in 2004. Prior to NEBS, he was Vice President and CFO of Nashua Corporation. He joined Nashua Corporation in 1984 and held financial management positions of increasing responsibility before becoming CFO in 1996. Mr. Junius holds a Masters in Management from Northwestern University's Kellogg School of Management.

John M. Lambert, Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer

John M. Lambert joined ImmunoGen as Senior Director of Research in 1987 and was promoted to Vice President, Research and Development in 1994, to Senior Vice President, Pharmaceutical Development in 2000, to Senior Vice President, Research and Development and Chief Scientific Officer in early 2008, and to Executive Vice President, Research and Development and Chief Scientific Officer in July 2008. Prior to his tenure with ImmunoGen, Dr. Lambert was Assistant Professor of Pathology at the Dana-Farber Cancer Institute in Boston, MA. Dr. Lambert received his doctorate in Biochemistry from Cambridge University in England.

Gregory Perry Senior Vice President and Chief Financial Officer

Before joining ImmunoGen in January 2009, Mr. Perry was CFO of Elixir Pharmaceuticals, Inc., where he was extensively involved in partnering and fundraising activities. Prior to Elixir, he was CFO of Domantis, Ltd., an antibody-related therapeutics company acquired by GlaxoSmithKline in 2006. Previously, Mr. Perry was Senior Vice President of Finance and CFO at Transkaryotic Therapies, Inc. (TKT) until its acquisition by Shire plc. in 2005. Before joining TKT in 2003, Mr. Perry held positions of increasing responsibility during his five years at PerkinElmer, Inc., rising to Senior Vice President, Finance and Business Development, Life Sciences. Prior to PerkinElmer, Mr. Perry spent the early part of his career at General Electric, joining the company’s financial management program in 1982 and departing in 1996 as Vice President and CFO, GE Medical Systems – Europe, after numerous promotions.

Suzanne Cadden Vice President, Regulatory & Quality

Prior to joining ImmunoGen in December 2009, Ms. Cadden was Vice President of Regulatory Affairs & Clinical Development at Sierra Neuropharmaceuticals Inc., where she was responsible for developing global regulatory and clinical strategies for novel therapeutics with a focus on the US and Europe. Before that, she was Vice President of Regulatory Affairs & Clinical Operations at ActivBiotics Inc. in Boston, MA, where she oversaw the development of global regulatory/clinical strategies, including Phase II and III clinical programs. Before joining ActivBiotics Inc., Ms. Cadden held senior positions at Transition Therapeutics, LORUS Therapeutics, Glaxo Wellcome, Inc. and CIBA, Canada. Ms. Cadden has published in her areas of expertise and holds a M.Sc. in Pharmacology from the University of Western Ontario and a B.Sc. in Biochemistry & Nutrition from the University of Guelph.

James O'Leary, MD Vice President and Chief Medical Officer

Prior to joining ImmunoGen in November 2008, Dr. O'Leary was Senior Medical Director, Clinical Oncology at Bayer Corporation, where his responsibilities included leading the global clinical development team for a late-stage anticancer agent. Before joining Bayer in 2006, he was Medical Director, Clinical Oncology at Pfizer Inc. While at Pfizer, Dr. O'Leary led early clinical development teams for two anticancer agents and, later, the global clinical development team for a more advanced compound. Prior to joining Pfizer as Associate Medical Director in 2000, Dr. O'Leary held the position of Medical Reviewer, Division of Oncology Drug Products, at the US Food and Drug Administration (FDA) and was the lead reviewer on Taxol(R) (paclitaxel) for adjuvant use in the treatment of breast cancer.

Dr. O'Leary completed his post-doctoral training in Internal Medicine at Winthrop University Hospital, his Hematology/Oncology fellowship at New York University Medical Center, and was a Sessions Physician at Bellevue Hospital in the Breast and the Oncology Clinics in New York. He earned his medical degree from the State University of New York - Health Science Center at Brooklyn in 1990.

Peter Williams Vice President, Business Development

Mr. Williams brings to ImmunoGen over twenty years of business development, deal negotiation and technology in- and out-licensing experience. Prior to joining ImmunoGen in August 2009, he was Senior Director of Business Development at Alnylam Pharmaceuticals, Inc., where he played a central role in the successful execution of large out-licensing and alliance transactions with global pharmaceutical companies. His positions prior to joining Alnylam include being Senior Director of Business Development at Millennium Pharmaceuticals, where he led several major alliances and transactions, and Associate Director, Office of Technology Licensing & Industry Sponsored Research, at Harvard Medical School, where he led activities related to commercializing in-house technology innovations. Mr. Williams has a Masters of Science degree in Management Science (accredited MBA) from the Imperial College of Science, Technology & Medicine, University of London, UK, and a Bachelors of Science degree in Biology from the University of Sussex, UK.

Craig Barrows Vice President, General Counsel and Secretary

Craig Barrows joined ImmunoGen in October 2007 with over twenty years of legal experience – thirteen as chief corporate legal officer – and a strong transactional background. Mr. Barrows was general counsel of M/A-COM, Inc. from 1994 until the company was acquired in 1996, general counsel and secretary of Media 100 Inc. before he joined New England Business Service, Inc. (NEBS) in 1998, and vice president, general counsel and secretary of NEBS until the company was acquired in 2004. Most recently, Mr. Barrows was vice president, general counsel and assistant secretary of Mercury Computer Systems, Inc. Before transitioning to in-house counsel, Mr. Barrows focused on corporate and securities law at Skadden, Arps, Slate, Meagher & Flom. He earned his undergraduate degree at the University of Chicago and his law degree at Fordham University School of Law.